source
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.BioPharma Dive · 14d ago↗ source
- Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trialAt the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…